Surgical Endoscopy · Nov 17, 2026
Glucagon-like peptide-1 receptor agonist use is associated with higher severity of acute pancreatitis
By Urias E, Panchal S, Hatipoglu D et al.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for obesity, type 2 diabetes, and MASLD. Although an association with pancreatitis has been reported, the clinical features, severity, and course of acute pancreatitis in patients receiving GLP-1RA therapy remain poorly characterized. We aimed to compare pancreatitis severity and outcomes in patients with and without GLP-1RA exposure. Methods: We conducted a retrospective cohort study of patients admitted with acute pancreatitis from March 2017 to August 2024. Patients were stratified by GLP-1RA exposure for at least 3 months prior to diagnosis. The primary outcome was disease severity measured by the Bedside Index for Severity in Acute Pancreatitis (BISAP). Secondary outcomes included liver biochemical abnormalities (AST, ALT, ALP, bilirubin), imaging findings, clinical complications, length of stay, and post-pancreatitis sequelae. An exploratory analysis compared biliary pathology (gallstones, choledocholithiasis, or biliary sludge) between GLP-1RA users with antecedent weight loss and patients with prior bariatric surgery. Results: Among 149 patients, 49 (32.9%) were receiving a GLP-1RA. In adjusted analysis, GLP-1RA use was independently associated with a BISAP score ≥ 2 (OR 5.25, 95% CI 1.13–24.34, p = 0.034), and increasing age was also associated with higher severity (OR 1.07, 95% CI 1.03–1.12, p = 0.001). GLP-1RA users had higher rates of pancreatitis-associated ascites but lower rates of new-onset diabetes and exocrine pancreatic insufficiency, with no significant differences in other clinical outcomes. GLP-1RA users exhibited greater antecedent weight loss ( p < 0.001), but biliary pathology did not differ significantly between groups. Conclusions: GLP-1RA use was associated with higher predicted severity of pancreatitis at presentation, reflected by a greater probability of a BISAP score ≥ 2, without a corresponding increase in post-pancreatitis complications. Nearly, half of GLP-1RA users developed pancreatitis within 1 year of therapy initiation. Most experienced antecedent weight loss, raising concern for a biliary contribution, although biliary pathology was observed both with the gallbladder in situ and after prior cholecystectomy.